Smac mimetics as IAP antagonists

Seminars in Cell and Developmental Biology

Volumn 39, Issue , 2015, Pages 132-138

  Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cancer; Cell death; IAP proteins; Smac mimetic

Indexed keywords

AZACITIDINE; BORTEZOMIB; CYTARABINE; DEATH RECEPTOR 5; DECITABINE; DEXAMETHASONE; DOXORUBICIN; FAS LIGAND; GEMCITABINE; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; INTERFERON REGULATORY FACTOR 1; MELPHALAN; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; OLIGONUCLEOTIDE; ONCOLYTIC VIRUS; PACLITAXEL; PEPTIDOMIMETIC AGENT; PREDNISOLONE; PROTEIN INHIBITOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOMIMETIC MATERIAL; OLIGOPEPTIDE; SMAC PEPTIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CYTOKINE RELEASE; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; GAMMA IRRADIATION; HUMAN; INNATE IMMUNITY; NECROPTOSIS; NONHUMAN; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMIMETIC MATERIALS; CELL DEATH; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; OLIGOPEPTIDES;

EID: 84928206377     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.12.005     Document Type: Review

References (60)

1. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012, 11:109-124.
2. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.H., Keats J.J., Wang H., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008, 9:1364-1370.
3. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008, 9:1371-1378.
4. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12:695-708.
5. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
6. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
7. Liu Z., Sun C., Olejniczak E.T., Meadows R.P., Betz S.F., Oost T., et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000, 408:1004-1008.
8. Wu G., Chai J., Suber T.L., Wu J.W., Du C., Wang X., et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000, 408:1008-1012.
9. Eckhardt I., Roesler S., Fulda S. Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis 2013, 4:e936.
10. Eckhardt I., Weigert A., Fulda S. Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response. Cell Death Dis 2014, 5:e1562.
11. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002, 8:808-815.
12. Stadel D., Cristofanon S., Abhari B.A., Deshayes K., Zobel K., Vucic D., et al. Requirement of nuclear factor kappaB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. Neoplasia 2011, 13:1162-1170.
13. Cheng Y.J., Jiang H.S., Hsu S.L., Lin L.C., Wu C.L., Ghanta V.K., et al. XIAP-mediated protection of H460 lung cancer cells against cisplatin. Eur J Pharmacol 2010, 627:75-84.
14. Loeder S., Fakler M., Schoeneberger H., Cristofanon S., Leibacher J., Vanlangenakker N., et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012, 26:1020-1029.
15. Carter B.Z., Gronda M., Wang Z., Welsh K., Pinilla C., Andreeff M., et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005, 105:4043-4050.
16. Dean E.J., Ward T., Pinilla C., Houghten R., Welsh K., Makin G., et al. A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. Br J Cancer 2010, 102:97-103.
17. Probst B.L., Liu L., Ramesh V., Li L., Sun H., Minna J.D., et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 2010, 17:1645-1654.
18. Bockbrader K.M., Tan M., Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005, 24:7381-7388.
19. Metwalli A.R., Khanbolooki S., Jinesh G., Sundi D., Shah J.B., Shrader M., et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 2010, 10:885-892.
20. Chauhan D., Neri P., Velankar M., Podar K., Hideshima T., Fulciniti M., et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007, 109:1220-1227.
21. Guo F., Nimmanapalli R., Paranawithana S., Wittman S., Griffin D., Bali P., et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002, 99:3419-3426.
22. Ziegler D.S., Keating J., Kesari S., Fast E.M., Zawel L., Ramakrishna N., et al. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro Oncol 2011, 13:820-829.
23. Servida F., Lecis D., Scavullo C., Drago C., Seneci P., Carlo-Stella C., et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest New Drugs 2011, 29:1264-1275.
24. Dineen S.P., Roland C.L., Greer R., Carbon J.G., Toombs J.E., Gupta P., et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010, 70:2852-2861.
25. Fandy T.E., Shankar S., Srivastava R.K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008, 7:60.
26. Wagner L., Marschall V., Karl S., Cristofanon S., Zobel K., Deshayes K., et al. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene 2013, 32:988-997.
27. Chromik J., Safferthal C., Serve H., Fulda S. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 2014, 344:101-109.
28. Belz K., Schoeneberger H., Wehner S., Weigert A., Bonig H., Klingebiel T., et al. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 2014, 124:240-250.
29. Stadel D., Mohr A., Ref C., MacFarlane M., Zhou S., Humphreys R., et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010, 16:5734-5749.
30. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009, 69:2425-2434.
31. Loeder S., Zenz T., Schnaiter A., Mertens D., Winkler D., Dohner H., et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009, 69:8977-8986.
32. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113:1710-1722.
33. Fingas C.D., Blechacz B.R., Smoot R.L., Guicciardi M.E., Mott J., Bronk S.F., et al. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 2010, 52:550-561.
34. Loeder S., Drensek A., Jeremias I., Debatin K.M., Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010, 126:2216-2228.
35. Geserick P., Hupe M., Moulin M., Wong W.W., Feoktistova M., Kellert B., et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 2009, 187:1037-1054.
36. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
37. Vellanki S.H., Grabrucker A., Liebau S., Proepper C., Eramo A., Braun V., et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009, 11:743-752.
38. Giagkousiklidis S., Vellanki S.H., Debatin K.M., Fulda S. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007, 26:7006-7016.
39. Berger R., Jennewein C., Marschall V., Karl S., Cristofanon S., Wagner L., et al. NF-{kappa}B is required for Smac mimetic-mediated sensitization of glioblastoma cells for {gamma}-irradiation-induced apoptosis. Mol Cancer Ther 2011, 10:1867-1875.
40. Vucic D., Franklin M.C., Wallweber H.J.A., Das K., Eckelman B.P., Shin H., et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005, 385:11-20.
41. Steinhart L., Belz K., Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013, 4:e802.
42. Carter B.Z., Mak P.Y., Mak D.H., Shi Y., Qiu Y., Bogenberger J.M., et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst 2014, 106:djt440.
43. Weisberg E., Ray A., Barrett R., Nelson E., Christie A.L., Porter D., et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010, 24:2100-2109.
44. Weisberg E., Kung A.L., Wright R.D., Moreno D., Catley L., Ray A., et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007, 6:1951-1961.
45. Ziegler D.S., Wright R.D., Kesari S., Lemieux M.E., Tran M.A., Jain M., et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 2008, 118:3109-3122.
46. Lecis D., Drago C., Manzoni L., Seneci P., Scolastico C., Mastrangelo E., et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 2010, 102:1707-1716.
47. Foster F.M., Owens T.W., Tanianis-Hughes J., Clarke R.B., Brennan K., Bundred N.J., et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 2009, 11:R41.
48. Beug S.T., Tang V.A., LaCasse E.C., Cheung H.H., Beauregard C.E., Brun J., et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 2014, 32:182-190.
49. Bake V., Roesler S., Eckhardt I., Belz K., Fulda S. Synergistic interaction of Smac mimetic and IFNalpha to trigger apoptosis in acute myeloid leukemia cells. Cancer Lett 2014, 355:224-231.
50. Jinesh G.G., Chunduru S., Kamat A.M. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and FasL. J Leukoc Biol 2012, 92:233-244.
51. Vanden Berghe T., Linkermann A., Jouan-Lanhouet S., Walczak H., Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014, 15:135-147.
52. Laukens B., Jennewein C., Schenk B., Vanlangenakker N., Schier A., Cristofanon S., et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011, 13:971-979.
53. Vanlangenakker N., Vanden Berghe T., Bogaert P., Laukens B., Zobel K., Deshayes K., et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ 2011, 18:656-665.
54. Amaravadi R.K., Schilder R.J., Dy G.K., Ma W.W., Fetterly G.J., Weng D.E., et al. Phase I study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors & lymphoma to evaluate safety, pharmocokinetics, pharmocodynamics and anti-tumor activity. Proceedings of the 102nd annual meeting of the American Association of Cancer Research 2011.
55. Infante J.R., Dees E.C., Burris H.A., Zawel L., Sager J.A., Stevenson C., et al. A phase I study of LCL-161, an oral inhibitor, in patients with advanced cancer. Proceedings of the 100st Annual Meeting of the American Association for Cancer Research 2010.
56. Sikic B.I., Eckhardt S.G., Gallant G., Burris H.A., Camidge D.R., Covelas A.D., et al. Safety, pharmocokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP), in patients (Pts.) with advanced solid tumors: results of a Phase I study. J Clin Oncol 2011, 29:3008. [Meeting Abstracts].
57. Infante J.R., Dees E.C., Olszanski A.J., Dhuria S.V., Sen S., Cameron S., et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014, 32:3103-3110.
58. Ikeda F., Deribe Y.L., Skanland S.S., Stieglitz B., Grabbe C., Franz-Wachtel M., et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 2011, 471:637-641.
59. Gerlach B., Cordier S.M., Schmukle A.C., Emmerich C.H., Rieser E., Haas T.L., et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011, 471:591-596.
60. Tokunaga F., Nakagawa T., Nakahara M., Saeki Y., Taniguchi M., Sakata S., et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature 2011, 471:633-636.